|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 164.97 USD | +1.67% |
|
-1.27% | +33.96% |
| Dec. 10 | This Is Decision Day |  |
| Dec. 10 | Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix… | |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Pharmaceutical Products | 2.36B | 3.09B | 3.66B | 3.83B | 4.07B | |||||
Total Assets | 6.54B | 12.3B | 10.84B | 11.39B | 12.01B | |||||
Interest Expense | -94.62M | -279M | -300M | -355M | -344M | |||||
Income Tax Expense | 33.52M | 216M | -159M | -120M | -91.43M | |||||
CAPEX | -379M | -45.53M | -29.05M | -23.96M | -38.07M | |||||
EBT | 275M | -113M | -373M | 298M | 470M | |||||
D&A | 278M | 552M | 629M | 639M | 660M | |||||
Operating Income | 378M | 170M | -65.53M | 579M | 717M | |||||
Net Income | 239M | -330M | -224M | 415M | 560M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 2.14B | 2.82B | 3.37B | 3.49B | 3.66B | |||||
Total Assets | 157M | 76.29M | 63.56M | 59.44M | 33.72M | |||||
Total Assets | 71.91M | 65.48M | 71.28M | 68.2M | 85.7M | |||||
Total Assets | 16.01M | 16.7M | 15.77M | 20.94M | 21.93M | |||||
Total Assets | - | 177M | 144M | 80.29M | 77.74M | |||||
Europe | 175M | 230M | 240M | 269M | 313M | |||||
Other | 43.82M | 43.84M | 49.36M | 74.98M | 96.14M | |||||
Total Assets | 11.91M | 8.18M | 6.9M | 6.11M | 7.9M |
- Stock Market
- Equities
- JAZZ Stock
- Financials Jazz Pharmaceuticals plc
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
